Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. - Wikidata - awgldk - TriplyDB

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

http://www.wikidata.org/entity/Q34417339

about

Recent developments in Alzheimer's disease therapeutics Clinical immunologic approaches for the treatment of Alzheimer's disease Immunotherapy as treatment for Alzheimer’s disease Vitamin A and Alzheimer's disease Prevention of Alzheimer's disease Alzheimer mechanisms and therapeutic strategies Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's disease Plasma and CSF Abeta for the longitudinal prediction of Alzheimer's disease dementia and other dementias in people with cognitive decline but no dementia Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases Active and passive immunotherapy for neurodegenerative disorders Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch The Rationale for Insulin Therapy in Alzheimer's Disease Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges The amyloid hypothesis of Alzheimer's disease at 25 years Current Research Therapeutic Strategies for Alzheimer's Disease Treatment Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Anti-dementia medications: current prescriptions in clinical practice and new agents in progress Immunotherapy for Alzheimer's disease: hoops and hurdles Alzheimer's therapeutics: translation of preclinical science to clinical drug development Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals Alzheimer disease immunotherapeutics: then and now 'Clinical trials in Alzheimer's disease': immunotherapy approaches Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target CD4 T cells in immunity and immunotherapy of Alzheimer's disease Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid -related Behavioral Deficits in a Mouse Model of Alzheimer Disease Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β Advancing translational research with the Semantic Web Alzheimer's disease: Targeting the Cholinergic System Immunotherapeutic approaches for Alzheimer's disease Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques Pathogenesis of Alzheimer's disease Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice

P2860

Q21245264-489D79E8-34E9-43BE-BCCE-5C74078D1CEB Q22241380-7C39923A-9B00-4B05-B731-03D76AB5667F Q22241491-20123D47-AC2E-4AE2-B2D2-EB318CD7E952 Q22242414-A6E67459-06BA-4EB1-A59E-C12ADD4558B9 Q22248031-2967823C-F6D5-497E-A0C5-12648F2C6468 Q22252311-A0ACD731-4687-44E6-A8D7-9C6CFE67548B Q24197852-44F28429-591B-4D24-A534-FE59DA3F8804 Q24235058-C77B6DFA-A4AE-499D-8434-D596BC9486C3 Q24599108-C3F71EB0-A05A-46C5-9FF1-EFA9C0A5BDB1 Q24622136-F0A99974-A8A5-4A76-A643-A3C6F2F51B90 Q24650014-76C27F8B-767A-4953-B359-A5C31BB05D6B Q24657879-9C94878A-5590-489F-8F73-8CD52B206B4D Q24676179-929329FD-5E0B-4756-9DDA-C55137188076 Q26744834-4C57AC12-C093-458D-8097-F9545BEED3EE Q26745928-8270603C-82CD-4CF6-92C5-EE4427E60495 Q26749528-F103C73F-81EA-4142-8379-F1229013EBEE Q26765530-0BEC4558-6D5F-4C9E-B356-7BC19FD57541 Q26784569-0AE0DDBC-3685-4658-BD3C-ACE5F3CCB03A Q26795400-B7A7780A-E28F-4680-AEAC-D49CD9A764EF Q26823877-37AE11D6-F3AF-42C8-A034-007BBE57D825 Q26829267-61CB36A5-D7B6-497F-B757-41F91D8F10BD Q26995405-E2247957-B911-4A3F-88ED-062E0A27C0BB Q27001031-16F27632-8B8D-4514-B864-FF4AA355FFAA Q27008979-F0A51B6A-4849-4B78-B0C8-3A934A791075 Q27021159-6B52DD41-F22B-4416-9972-61E2C20CDB34 Q27024202-35687E83-7024-4CCB-8A25-E1B2F6B53199 Q27334874-65BA40C0-C5B2-431E-8C62-79C11D9A29C2 Q27349010-1BF08334-7F57-4590-A884-6AD45A7BEE38 Q27658233-D5602D4D-64CC-4837-805C-AB1B1D25503B Q27682022-7737A18F-844D-4886-B20D-137D998F5D74 Q27990958-BDBFB522-BABE-4002-B5AA-3C05C8345C19 Q28070135-027B4D3C-D132-41EE-8119-8105769EB485 Q28081278-D226093F-4157-45D6-90E9-6D21CCE75202 Q28488690-16B91060-7CAC-43E2-A3A2-CF75FD1E553D Q28581962-D4E499B1-411C-4B86-828E-28D1148B5A3A Q28740910-33CC35B0-1086-44E8-8F18-ACA3F22D3815 Q30439489-865C8E44-F4FF-4BF3-94BD-D2752A09A704 Q30486176-4A7BA892-20A7-4F18-9220-3210E66A003B Q30513293-D88725F3-C8A5-4AE2-9489-51D1453983E8 Q30579707-27E797B2-6809-4619-BFF8-597B78ADB739

P2860

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

http://www.wikidata.org/entity/Q34417339

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Clinical effects of Abeta immu ...... th AD in an interrupted trial.

@ast

Clinical effects of Abeta immu ...... th AD in an interrupted trial.

@en

Clinical effects of Abeta immunization

@nl

type

label

Clinical effects of Abeta immu ...... th AD in an interrupted trial.

@ast

Clinical effects of Abeta immu ...... th AD in an interrupted trial.

@en

Clinical effects of Abeta immunization

@nl

prefLabel

Clinical effects of Abeta immu ...... th AD in an interrupted trial.

@ast

Clinical effects of Abeta immu ...... th AD in an interrupted trial.

@en

Clinical effects of Abeta immunization

@nl

P1433

Q34417339-3CFA4C07-84ED-483D-8C38-4F9CB9E29986

P1476

Q34417339-030BB994-E661-4277-B7C9-663E7EE53968

P2093

Q34417339-11B81C27-D17E-4C75-AB3D-56E6FDF1F303

Q34417339-131BF97A-F181-4FFA-BEED-1CD4B2C37E9C

Q34417339-18408360-A0DA-434F-A597-8A967FBFF19A

Q34417339-19A47F7C-067D-41B0-B075-F3323F212D4C

Q34417339-1F020DBD-00AB-4434-B381-700D25D593B6

Q34417339-361C02D8-D4A5-4E3B-A683-485607F98817

Q34417339-41E30691-FACD-4D73-B9C2-7C221D299C34

Q34417339-61BCB10B-78F2-4038-B939-2DE5FCF1F77A

Q34417339-6F2D0563-1872-457B-8478-56142E9167DD

Q34417339-9C1898C9-5199-496D-A9C8-C9BFD708B7D4

P304

Q34417339-A17A5B30-87FC-402C-8D30-6892517140DB

P31

Q34417339-FEDB98EC-8B24-4D94-A074-DD6A32D03F5B

P356

Q34417339-5E4BCBF5-56BC-4886-A23D-656621C35CF8

P407

Q34417339-16DFDB1D-395F-4011-B81D-547FEBEC457D

P433

Q34417339-61DB2D53-0CD0-4F61-AACF-E317BF441054

P478

Q34417339-6AD90842-81D5-4695-99A6-850BDFE77AB9

P50

Q34417339-EB877A5F-C67E-4706-BF57-C32CA4A64EA7

P577

Q34417339-674D3D49-1100-4776-A7B7-2331AD9F0012

P5875

Q34417339-710656A5-35E4-4CFD-8013-8C96FC185A9A

P698

Q34417339-CBF98A29-0D52-4B64-B4EF-695729C51D88

P921

Q34417339-9C4C54BA-AAB7-42C7-BF69-3944AC684492

P356

01.WNL.0000159740.16984.3C

P1433

P1476

Clinical effects of Abeta immu ...... ith AD in an interrupted trial

@en

P2093

AN1792(QS-21)-201 Study Team

http://www.w3.org/2001/XMLSchema#string

F Forette

http://www.w3.org/2001/XMLSchema#string

J-M Orgogozo

http://www.w3.org/2001/XMLSchema#string

L Eisner

http://www.w3.org/2001/XMLSchema#string

L Jenkins

http://www.w3.org/2001/XMLSchema#string

L Kirby

http://www.w3.org/2001/XMLSchema#string

M Boada Rovira

http://www.w3.org/2001/XMLSchema#string

M Koller

http://www.w3.org/2001/XMLSchema#string

R S Black

http://www.w3.org/2001/XMLSchema#string

S G Griffith

http://www.w3.org/2001/XMLSchema#string

P304

1553-1562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/01.WNL.0000159740.16984.3C

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7858425

http://www.w3.org/2001/XMLSchema#string

P698

15883316

http://www.w3.org/2001/XMLSchema#string

P921